Low-dose OKT3 induction therapy following renal transplantation leads to improved graft function and decreased adverse effects.
Brown
M
M
Washington Hospital Center, Washington, DC 20010.
Korb
S
S
Light
J A
JA
Light
T
T
Jonsson
J
J
Aquino
A
A
D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D006084:Graft Rejection / Q000276:immunology; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D008297:Male; D016853:Muromonab-CD3 / Q000009:adverse effects / Q000627:therapeutic use*; D011183:Postoperative Complications; D013256:Steroids / Q000627:therapeutic use
D016853:Muromonab-CD3; D013256:Steroids; D016572:Cyclosporine; D001379:Azathioprine